Clinical Trials Browser

Phase 3 × aumolertinib × 1 year × Clear all

NCT07183189 2025-12-18

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung